No Impact With Mifepristone in Patients With Meningioma

Share this content:
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.

Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of failure-free or overall survival, according to a study published online ahead of print in the Journal of Clinical Oncology.1

In a multicenter, prospective, randomized, placebo-controlled phase 3 trial, researchers led by Yongli Ji, MD, of the University of Vermont Cancer Center in Burlington, VT, randomly assigned 164 patients to either mifepristone or placebo for 2 years or until disease progression.

Patients who were stable or had responded to therapy after 2 years had the option to continue therapy, and time to treatment failure and overall survival rate were measured.

RELATED: Proton Therapy Well-Tolerated for Low-Grade Gliomas

The researchers found that 24 patients were able to complete 2 years of mifepristone without disease progression, adverse effects, or other reasons for discontinuation. In addition, 28 patients in the placebo group were able to complete the 2-year study.

They observed no statistical difference between the 2 arms in terms of failure-free or overall survival, and concluded that long-term administration of mifepristone had no significant impact on this patient population.

Reference

  1. Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005 [published online ahead of print November 2, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.61.6490.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs